News
Click on the Recycle Bin (full) icon and select the Change Icon button. Select your full.ico image, then Apply and OK. Follow ...
GSK's six-monthly IL-5 inhibitor depemokimab clears two phase 3 trials in chronic rhinosinusitis with nasal polyps (CRSwNP), its second indication.
Regulators have started reviews of GSK's depemokimab, aiming to become the first drug for asthma that can be dosed twice a year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results